MULPLETA (Lusutrombopag) – Thrombocytopenia | HongKong DengYue Medicine

Lusutrombopag Application Scope

Indicated for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.

Lusutrombopag Characteristics

• Ingredients: Lusutrombopag

• Properties:​ Lusutrombopag is an orally available thrombopoietin (TPO) receptor agonist that stimulates megakaryopoiesis, leading to increased platelet production.

• Packaging Specification:​ Available as 3 mg light red, round, film-coated tablets debossed with the Shionogi trademark.

• Storage:​

  • Store in the original package to protect from moisture.

  • Does not require any special temperature storage conditions.

• Expiry Date: Refer to the last day of the month indicated on the carton and blisters.

• Executive Standard: ​Manufactured in compliance with applicable pharmaceutical manufacturing standards.

• Approval Number: Approved by the U.S. FDA on July 31, 2018.

• Date of Revision: Refer to the latest prescribing information for the most recent revision date.

• Manufacturer: Shionogi Inc., Florham Park, NJ 07932.

Guidelines for the Use of Lusutrombopag

• Dosage and Administration:

  • Recommended Dose: 3 mg once daily for 7 days.

  • Administration: Oral tablets taken with or without food.

  • Missed Dose:​ If a dose is missed, take it as soon as remembered unless it is less than 12 hours until the next dose. Do not double doses to make up for a missed dose.

• Adverse Reactions:

  • Common Adverse Reactions: Headache.

  • Serious Adverse Reactions:

    • Portal vein thrombosis (1% incidence in clinical trials).

    • Potential for increased thrombotic events if platelet counts rise too high.

    ​

• Contraindications: None identified

• Precautions:

  • Monitor platelet counts regularly during treatment.

  • Use with caution in patients with a history of thromboembolic events.

  • Not intended to normalize platelet counts in patients with chronic liver disease.

Lusutrombopag Interactions

• No significant drug interactions reported.

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.